Results 241 to 250 of about 376,311 (300)
Some of the next articles are maybe not open access.
Journal of Virological Methods, 1985
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +6 more sources
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +6 more sources
Journal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +3 more sources
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +3 more sources
Vaccine, 2003
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +4 more sources
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +4 more sources
Combination Hepatitis A-Hepatitis B Vaccine
BioDrugs, 1997The adult formulation of this combination hepatitis A-hepatitis B vaccine contains 720 enzyme-linked immunosorbent assay units (EU) of formalin-inactivated hepatitis A virus strain HM175 and 20mug of recombinant DNA yeast-derived hepatitis B surface antigen adsorbed onto aluminium salts in 1ml for injection.
Julia A. Balfour, Antona J. Wagstaff
openaire +3 more sources
Vaccine, 1983
Abstract Hepatitis B is endemic in many African, Asian and Pacific countries causing much debilitation and death. The disease can lead to chronic cirrhosis and is closely associated with liver cell cancer. There are in the order of 200 million people that carry the virus and constitute a huge reservoir of infection.
openaire +3 more sources
Abstract Hepatitis B is endemic in many African, Asian and Pacific countries causing much debilitation and death. The disease can lead to chronic cirrhosis and is closely associated with liver cell cancer. There are in the order of 200 million people that carry the virus and constitute a huge reservoir of infection.
openaire +3 more sources
A review of hepatitis B vaccination
Expert Opinion on Drug Safety, 2003Hepatitis B is one of the most important infectious causes of acute and chronic liver disease both in the US and worldwide. In order to combat the life-threatening effects of hepatitis B infection, recombinant hepatitis B vaccines have been developed.
Arthur C. Zahalsky +2 more
openaire +3 more sources
Current Hepatitis Reports, 2006 Hepatitis B virus (HBV)infection is a major cause of chronic hepatitis and cirrhosis,with an estimated 350 million people worldwide infected with the virus.Despite continuing advances in antiviral therapy,a cure for chronic HBV infection is considered an elusive goal.Thus,primary prevention by immunization with HBV vaccines remains the most effective ...
Henry C. Bodenheimer +2 more
openaire +1 more source
Hepatitis B and A vaccines [PDF]
, 1989 Hepatitis has been recognized as a serious disease throughout recorded history. Outbreaks of jaundice came to be recognized over time as potentially infectious in nature. The confirmation of a viral aetiology to certain forms of hepatitis was established in the early 1940s in studies in human volunteers to whom hepatitis could be transmitted by a non ...
P. J. Provost, R. W. Ellis
openaire +1 more source
, 1988 The first results of active immunization against hepatitis B in humans were reported a little over 10 years ago (Maupas et al., 1976). Since then, several serum-derived hepatitis B (HB) vaccines have been proved safe, highly immunogenic and efficacious in various populations at risk (Stevens et al., 1984).
F. Tron +8 more
openaire +1 more source
, 1999 Hepatitis B virus (HBV) chronically infects 200–300 million people worldwide. The resulting acute and chronic disease that results from contact with these individuals or their blood is a leading cause of liver disease, including hepatocellular carcinoma, and mortality. In fact, HBV is second only to smoking as a cause of human cancers (1).
openaire +1 more source